These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8221656)
1. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Kieback DG; McCamant SK; Press MF; Atkinson EN; Gallager HS; Edwards CL; Hajek RA; Jones LA Cancer Res; 1993 Nov; 53(21):5188-92. PubMed ID: 8221656 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL). Kieback DG; Press MF; Atkinson EN; Edwards GL; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA Anticancer Res; 1993; 13(6B):2489-96. PubMed ID: 8135488 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777 [TBL] [Abstract][Full Text] [Related]
4. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression]. Kieback DG; Press MF; McCamant SK; Atkinson EN; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):189-94. PubMed ID: 7789706 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554 [TBL] [Abstract][Full Text] [Related]
6. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Geisler JP; Wiemann MC; Miller GA; Geisler HE Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651 [TBL] [Abstract][Full Text] [Related]
7. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
8. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Salvesen HB; Iversen OE; Akslen LA Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742 [TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Chan KK; Wei N; Liu SS; Xiao-Yun L; Cheung AN; Ngan HY Obstet Gynecol; 2008 Jan; 111(1):144-51. PubMed ID: 18165403 [TBL] [Abstract][Full Text] [Related]
10. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Yang XY; Xi MR; Yang KX; Yu H Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934 [TBL] [Abstract][Full Text] [Related]
12. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829 [TBL] [Abstract][Full Text] [Related]
13. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566 [TBL] [Abstract][Full Text] [Related]
14. Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancers? Schwartz PE; MacLusky N; Merino MJ; Livolsi VA; Kohorn EI; Eisenfeld A Obstet Gynecol; 1986 Dec; 68(6):751-8. PubMed ID: 3785785 [TBL] [Abstract][Full Text] [Related]
15. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189 [TBL] [Abstract][Full Text] [Related]
16. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812 [TBL] [Abstract][Full Text] [Related]
17. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Fine BA; Valente PT; Feinstein GI; Dey T Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438 [TBL] [Abstract][Full Text] [Related]
18. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436 [TBL] [Abstract][Full Text] [Related]
19. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Fischer-Colbrie J; Witt A; Heinzl H; Speiser P; Czerwenka K; Sevelda P; Zeillinger R Anticancer Res; 1997; 17(1B):613-9. PubMed ID: 9066588 [TBL] [Abstract][Full Text] [Related]
20. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]